Atara Biotherapeutics Inc Total Liabilities
Atara Biotherapeutics Inc total liabilities. Based on the latest financial reports, Atara Biotherapeutics Inc (ATRA) has total liabilities worth $66.80 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Atara Biotherapeutics Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Atara Biotherapeutics Inc (2012–2024)
Total liabilities of Atara Biotherapeutics Inc from 2012 to 2024. This chart illustrates how Atara Biotherapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Atara Biotherapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Atara Biotherapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PJP Makrum S.A.
WAR:PJP
|
Poland | zł484.75 Million |
|
PetVivo Holdings Inc
NASDAQ:PETV
|
USA | $3.16 Million |
|
Wisr Ltd
AU:WZR
|
Australia | AU$976.80 Million |
|
Atlanta Poland SA
WAR:ATP
|
Poland | zł104.82 Million |
|
Pancontinental Energy NL
AU:PCL
|
Australia | AU$580.18K |
|
Nephros Inc
NASDAQ:NEPH
|
USA | $3.09 Million |
|
TJ media Co. Ltd
KQ:032540
|
Korea | ₩43.56 Billion |
|
Mind Technology Inc
NASDAQ:MIND
|
USA | $7.40 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Atara Biotherapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Atara Biotherapeutics Inc asset portfolio.
Liquidity & Leverage Metrics
Atara Biotherapeutics Inc Total Liabilities Ratios Explained
Atara Biotherapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Atara Biotherapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Atara Biotherapeutics Inc (2012–2024)
The table below shows the annual total liabilities of Atara Biotherapeutics Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $206.38 Million | -22.04% |
| 2023-12-31 | $264.74 Million | +5.99% |
| 2022-12-31 | $249.78 Million | +32.50% |
| 2021-12-31 | $188.51 Million | +49.87% |
| 2020-12-31 | $125.78 Million | +141.14% |
| 2019-12-31 | $52.16 Million | -1.55% |
| 2018-12-31 | $52.98 Million | +32.74% |
| 2017-12-31 | $39.91 Million | +292.17% |
| 2016-12-31 | $10.18 Million | +3.07% |
| 2015-12-31 | $9.88 Million | +235.88% |
| 2014-12-31 | $2.94 Million | -95.32% |
| 2013-12-31 | $62.84 Million | +683.90% |
| 2012-12-31 | $8.02 Million | -- |
About Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as… Read more